Clinical trials: Acute Ischemic Stroke Patients
Acute Ischemic Stroke
Safety and Efficacy Evaluation of the Ceretrieve Device in the Treatment of AIS Patients
The main objective of this clinical trial is to evaluate of the safety \& efficacy of the Ceretrieve device within 24 hours post thrombectomy procedure.
- Trial name
- NCT06733246
- Testing
- Aspiration 0
- Where
- Germany
- Volunteers
- 132 people
- Sponsor
- Ceretrieve Ltd.
Acute Ischemic Stroke
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke
This multi-center, randomized, parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of TB006 in participants with an Acute Ischemic Stroke (AIS) event with 57 days of treatment.
- Trial name
- NCT05156827
- Testing
- TB006
- Sponsor
- TrueBinding, Inc.
Acute Stroke
Cytoflavin in Combination With Reperfusion in Stroke Patients
Evaluation of the efficacy and safety of Cytoflavin®, solution for intravenous administration, (OOO NTFF POLYSAN, Russia) for 10 days, patients with cerebral infarction who receive reperfusion therapy, with the start of treatment…
- Trial name
- NCT05297851
- Testing
- Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin), Control
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Acute Ischemic Stroke
Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)
Though intravenous thrombolysis has been shown to improve symptoms in acute ischemic stroke patients, the recanalization rate remains low (22.6%) and only around 30% of patients benefit from the treatment.
- Trial name
- NCT06677970
- Testing
- BP lowering drugs (nicardipine, labetalol, urapidil), BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil)
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Yonsei University
Cerebrovascular Stroke, Atrial Fibrillation
Prediction and Detection of Occult Atrial Fibrillation in Patients After Acute Cryptogenic Stroke and TIA
PROACTIA is a prospective, event-driven observational study. It aims to propose a composite scoring system in order to evaluate the risk of paroxysmal atrial fibrillation (PAF) in patients after acute cryptogenic stroke and…
- Trial name
- PROACTIA (NCT02725944)
- Testing
- Implantation of ICRM
- Where
- Norway
- Volunteers
- 251 people
- Sponsor
- University Hospital, Akershus
Stroke, Acute
Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements
The primary objectives of this study is to evaluate the efficacy of HLCM051 on functional outcome in subjects with acute ischemic stroke and to evaluate the safety of HLCM051 in subjects with acute ischemic stroke.
- Trial name
- TREASURE (NCT02961504)
- Testing
- HLCM051
- Where
- Japan
- Volunteers
- 206 people
- Sponsor
- Healios K.K.
Ischemic Stroke
Efficacy and Safety of Mexidol® in Stroke Therapy
The main purpose of the clinical trial is to evaluate the efficacy and safety of Mexidol® in sequential treatment for patients in the acute and early recovery periods of ischemic stroke compared to placebo.
- Trial name
- MIR (NCT06437626)
- Testing
- Mexidol (Ethylmethylhydroxypyridine Succinate)
- Where
- 17 sites in Kazakhstan, Russia and 1 more
- Volunteers
- 304 people
- Sponsor
- Pharmasoft
Acute Ischemic Stroke
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
The aim is to assess the effects and harms of Xueshuantong lyophilized powder versus placebo in patients with acute ischemic stroke when initiated within 72 hours of symptom onset.
- Trial name
- EXPECT (NCT04415164)
- Testing
- Xueshuantong lyophilized powder, Guidelines-based standard care
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Dongzhimen Hospital, Beijing
Acute Ischemic Stroke
Effectiveness and Safety of Xiaoshuanchangrong (XSCR) Capsule for the Treatment of Patients Who Have Suffered From a Stroke
This study will determine if Xiaoshuanchangrong (XSCR) capsule will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strength and…
- Trial name
- NCT00710164
- Testing
- XSCR capsule (Composed of Traditional Chinese Medicine Huangqi, Chuanxiong, Chishao, Danggui, Dilong, Taoren, Honghua.)
- Where
- 20 sites in China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Ischemic Stroke
Efficacy of High and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcome in Patients With AIS
Patients with acute ischemic stroke will be divided into 2 groups by double-blind, randomized, and controlled trial. Personality and past history of the patients will be recorded after the patients signed inform consent.
- Trial name
- NCT03402204
- Testing
- Simvastatin 10 mg, Simvastatin 40 mg
- Volunteers
- 64 people
- Sponsor
- Thammasat University
Acute Ischemic Stroke
Study of Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients With a Large Infarct Core
Endovascular therapy (EVT) was recommended as the primary treatment for patients with acute large vascular occlusion (LVO) in anterior circulation.
- Trial name
- ANGEL-ASPECT (NCT04551664)
- Testing
- Best medical management, Endovascular therapy
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Beijing Tiantan Hospital
Ischemic Stroke
Clopidogrel Response in Acute Ischemic Stroke. The Bochumer CRISP Study
The aim of this study was to determine the prevalence rate and risk factors for chemical laboratory clopidogrel low-response (CLR) in the acute phase after an ischemic stroke.
- Trial name
- Bo-CRISP (NCT01843361)
- Where
- Germany
- Volunteers
- 159 people
- Sponsor
- Ruhr University of Bochum
Stroke, Acute
A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke
This clinical trial was planned for the purpose to re-evaluate the safety and efficacy of naloxone hydrochloride in ischemic cerebral nerve disorders caused by stroke and cerebral hemorrhage.
- Trial name
- NCT05301712
- Testing
- Naloxone hydrochloride 5.0mg/5ml, Sodium Chloride 45mg/5ml
- Where
- South Korea
- Volunteers
- 446 people
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
Acute Ischemic Stroke
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset.
- Trial name
- RAISE (NCT06226805)
- Testing
- BB-031
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 228 people
- Sponsor
- Basking Biosciences, Inc.
Ischemic Stroke, Acute, Post-stroke Anxiety
Benson Relaxation for Anxiety, Depression, and Insomnia After Stroke
Stroke is a leading cause of disability worldwide. Many patients experience anxiety, depression, and sleep disturbances in the early recovery phase, which can slow rehabilitation.
- Conditions
- Ischemic Stroke, Acute, Post-stroke Anxiety, Post-stroke Depression, Sleep
- Trial name
- BRT-Stroke (NCT07731282)
- Testing
- Benson Relaxation Technique, Structured Health Education
- Where
- 2 sites in China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Changchun University of Traditional Chinese Medicine
Acute Ischemic Stroke
Radial Versus Femoral Access For Thrombectomy in Patients With Acute Basilar Artery Occlusion
Stroke is one of the most important diseases endangering the health and quality of life of Chinese people. Acute ischemic stroke (AIS) is commonly caused by cerebrovascular stenosis or occlusion.
- Trial name
- NCT05903560
- Testing
- endovascular recanalization via radial approach, endovascular recanalization via femoral approach
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Jinling Hospital, China
Stroke, Transient Ischemic Attack
Copeptin for Risk Stratification in Acute Stroke Patients: the CoRisk Study
Prospective observational multicenter study to evaluate copeptin as a prognostic marker in patients with an acute cerebrovascular event.
- Trial name
- CoRisk (NCT00878813)
- Testing
- Sampling of 15ml blood, Blood-Sampling
- Where
- 4 sites in Germany, Switzerland
- Volunteers
- 1,102 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Ischemic Stroke
Neuroactive Steroids in Acute Ischemic Stroke
Despite several scientific and technological advances, there is no single neuroprotective treatment that can reverse the brain damage after acute ischemic stroke (AIS).
- Trial name
- NCT02914106
- Testing
- Observational Study
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hospital Militar Central, Argentina
Ischemic Stroke, Cortisol; Hypersecretion
Neuroactive Steroids in Acute Ischemic Stroke
Acute ischemic stroke (AIS) represents an economical challenge for health systems all over the globe. Despite increasing knowledge of the pathophysiology of AIS, there is no satisfactory treatment to revert the resulting brain…
- Trial name
- Cortisol (NCT03242304)
- Testing
- Behavioral tests
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Militar Central, Argentina
Stress Hyperglycemia
Stress Hyperglycemia and Acute Ischemic Stroke
Whereas diabetes mellitus is clearly a risk factor for the occurrence of stroke and for its poor prognosis, hyperglycemia per se is also linked to increased morbidity and mortality in stroke patients.Therefore, the objective of…
- Trial name
- NCT04408768
- Testing
- standard protocol for stroke patients
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University